Paul Hastings Advises Sciele Pharma in $325 Million Public Offering of Contingent Convertible Senior Notes

May 16, 2007

Paul Hastings Advises Sciele Pharma in $325 Million Public Offering of Contingent Convertible Senior Notes

Atlanta, GA (May 15, 2007) -- Paul, Hastings, Janofsky & Walker LLP (Paul Hastings), a leading international law firm, announced today that it advised Sciele Pharma, Inc. (NASDAQ: SCRX) in its $325 million public offering of 2.625% Contingent Convertible Senior Notes due 2027.

The Paul Hastings team was represented by partners Tinley Anderson, Elizabeth Noe and Joe Opich, and associates Karen Leach and Jared Brandman.

About Sciele Pharma, Inc. Sciele Pharma, Inc. is a pharmaceutical company specializing in sales, marketing and development of branded prescription products focused on Cardiovascular/Diabetes and Women's Health. The Company's Cardiovascular/Diabetes products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina and Type 2 diabetes, and its Women's Health products are designed to improve the health and well-being of women and mothers and their babies. Founded in 1992 and headquartered in Atlanta, Georgia, Sciele Pharma employs more than 800 people. The Company's success is based on placing the needs of patients first, improving health and quality of life, and implementing its business platform - an Entrepreneurial Spirit, Innovation, Speed of Execution, Simplicity, and Teamwork.

Paul Hastings Janofsky & Walker LLP, founded in 1951, is a leading international law firm with over 1,200 attorneys in 18 offices. The firm serves a diverse client base including many of the leading global financial institutions and Fortune 500 companies and offers deep capabilities in banking and finance, capital markets, corporate/M&A, litigation and dispute resolution, intellectual property, project finance, investment management, real estate, labor and employment and tax advisory services. For additional information, please visit our website at www.paulhastings.com.